-
公开(公告)号：WO2017218623A1
公开(公告)日：2017-12-21
申请号：PCT/US2017/037383
申请日：2017-06-14
Applicant: TARIX ORPHAN LLC
Inventor： FRANKLIN, Richard
IPC: A61K31/415 , A61K38/12 , A61P17/02
CPC classification number: A61P17/02 , A61K31/4178 , A61K38/085 , A61K38/12 , C07K7/14
Abstract: The present invention provides, among other things, method of treating epidermolysis bullosa including administering to a subject suffering from epidermolysis bullosa an angiotensin (1-7) peptide. In some embodiments, the present invention also provides methods of treating a complication of epidermolysis bullosa including ad ministering to a subject suffering from one or more complications of epidermolysis bullosa an angiotensin (1-7) peptide, wherein the ad ministration results in a reduction in the intensity, severity, duration, or frequency of at least one symptom or feature of the one or more complications of epidermolysis bullosa.
Abstract translation: 本发明提供了治疗大疱性表皮松解症的方法，包括向患有大疱性表皮松解症的患者施用血管紧张素（1-7）肽。 在一些实施方案中，本发明还提供了治疗大疱性表皮松解症的并发症的方法，包括向患有一种或多种大疱性表皮松解症和血管紧张素（1-7）肽的并发症的患者配药，其中所述给药导致 一种或多种大疱性表皮松解症并发症的至少一种症状或特征的强度，严重程度，持续时间或频率。
-
公开(公告)号：WO2017066552A1
公开(公告)日：2017-04-20
申请号：PCT/US2016/057016
申请日：2016-10-14
Applicant: TARIX PHARMACEUTICALS LTD.
Inventor： FRANKLIN, Richard
IPC: A61K38/08 , A61K38/12 , A61K31/415 , A61P17/02
CPC classification number: A61K31/4178 , A61K38/085
Abstract: The present invention provides, among other things, method of treating epidermolysis bullosa including administering to a subject suffering from epidermolysis bullosa an angiotensin (1-7) peptide. In some embodiments, the present invention also provides methods of treating a complication of epidermolysis bullosa including administering to a subject suffering from one or more complications of epidermolysis bullosa an angiotensin (1-7) peptide, wherein the administration results in a reduction in the intensity, severity, duration, or frequency of at least one symptom or feature of the one or more complications of epidermolysis bullosa.
Abstract translation: 本发明提供了治疗大疱性表皮松解症的方法，包括向患有大疱性表皮松解症的患者施用血管紧张素（1-7）肽。 在一些实施方案中，本发明还提供了治疗大疱性表皮松解症的并发症的方法，包括向患有一种或多种大疱性表皮松解症并发症的患者施用血管紧张素（1-7）肽，其中所述施用导致强度降低 ，大疱性表皮松解症的一种或多种并发症的至少一种症状或特征的严重程度，持续时间或频率。
-
公开(公告)号：WO2013090833A8
公开(公告)日：2014-07-17
申请号：PCT/US2012069930
申请日：2012-12-14
Applicant: TARIX PHARMACEUTICALS LTD , UNIV SOUTHERN CALIFORNIA
Inventor： BERINGER PAUL , FRANKLIN RICHARD
CPC classification number: A61K38/085 , A61K31/4178
Abstract: The present invention provides, among other things, methods and compositions for treating or preventing fibrotic diseases, disorders or conditions based on Angiotensin (1-7) polypeptides, and analogs or derivatives thereof. In some embodiments, compositions and methods for treating or preventing pulmonary fibrosis, pulmonary hypertension, chronic obstructive pulmonary disease (COPD), asthma, cystic fibrosis, kidney fibrosis, liver fibrosis, systemic sclerosis, post-surgical adhesions, accelerating wound healing, and reducing or preventing scar formation are provided.
Abstract translation: 本发明尤其提供了用于治疗或预防基于血管紧张素（1-7）多肽的纤维化疾病，病症或病症及其类似物或衍生物的方法和组合物。 在一些实施方案中，用于治疗或预防肺纤维化，肺动脉高压，慢性阻塞性肺病（COPD），哮喘，囊性纤维化，肾纤维化，肝纤维化，系统性硬化，手术后粘连，加速伤口愈合和减少的组合物和方法 或防止瘢痕形成。
-
公开(公告)号：WO2014043693A1
公开(公告)日：2014-03-20
申请号：PCT/US2013/060139
申请日：2013-09-17
Applicant: TARIX PHARMACEUTICALS LTD.
Inventor： FRANKLIN, Richard , STERN, William , VRYHOF, Austin
CPC classification number: A61K38/085 , A61K9/2013 , A61K9/4858 , A61K9/4891 , A61K31/401 , A61K38/12 , A61K47/48215 , A61K47/60
Abstract: The present invention provides various formulations for oral delivery of angiotensin peptides.
Abstract translation: 本发明提供用于口服递送血管紧张素肽的各种制剂。
-
公开(公告)号：WO2010028845A3
公开(公告)日：2010-06-10
申请号：PCT/EP2009006619
申请日：2009-09-11
Applicant: CHARITE UNIVERSITAETSMEDIZIN , WALTHER THOMAS , KUEBLER WOLFGANG
Inventor： WALTHER THOMAS , KUEBLER WOLFGANG
CPC classification number: A61K38/085 , A61K31/4178 , C07D409/10 , C07K7/14
Abstract: The present invention refers to a peptidic or non-peptidic angiotensin-(1-7) (Ang-(1-7)) receptor agonist, preferably a Mas receptor agonist, for the prevention and/or treatment of acute lung injury, preferably acute respiratory distress syndrome.
Abstract translation: 本发明涉及用于预防和/或治疗急性肺损伤的肽或非肽血管紧张素（1-7）（Ang-（1-7））受体激动剂，优选Mas受体激动剂，优选急性 呼吸窘迫综合征。
-
Patent Agency Ranking
公开(公告)号：WO2009114461A2
公开(公告)日：2009-09-17
申请号：PCT/US2009/036502
申请日：2009-03-09
Inventor： RODGERS, Kathleen, E. , DIZEREGA, Gere, S.
CPC classification number: A61K38/085 , A61K38/03
Abstract: The present invention provides angiotensin (1-7) pharmaceutical compositions, dosage forms, and methods for their use, and methods for treating or limiting development of acquired immune deficiency syndrome.
Abstract translation: 本发明提供血管紧张素（1-7）药物组合物，剂型及其使用方法，以及治疗或限制获得性免疫缺陷综合征发展的方法。
-
公开(公告)号：WO2009043456A2
公开(公告)日：2009-04-09
申请号：PCT/EP2008/007636
申请日：2008-09-09
Applicant: MONDOBIOTECH LABORATORIES AG , BEVEC, Dorian , CAVALLI, Fabio , CAVALLI, Vera , BACHER, Gerald
Inventor： BEVEC, Dorian , CAVALLI, Fabio , CAVALLI, Vera , BACHER, Gerald
IPC: A61K38/35 , A61P3/00 , A61P9/00 , A61P11/00 , A61P25/28 , A61P31/00 , A61P31/18 , A61P31/20 , A61P35/00 , A61P37/00
CPC classification number: A61K38/085 , A61K38/35 , Y02A50/385 , Y02A50/402 , Y02A50/409 , Y02A50/411 , Y02A50/414 , Y02A50/415 , Y02A50/422 , Y02A50/423
Abstract: The present invention is directed to the use of the peptide compound Val-Tyr-Pro-Asn-Gly-Ala-Glu-Asp-Glu-Ser-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Val-Tyr-Pro-Asn-Gly-Ala-Glu-Asp-Glu- Ser-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.
Abstract translation: 本发明涉及肽化合物Val-Tyr-Pro-Asn-Gly-Ala-Glu-Asp-Glu-Ser-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH的用途 用于预防和/或治疗癌症，自身免疫疾病，纤维化疾病，炎性疾病，神经变性疾病，感染性疾病，肺部疾病，心脏和血管疾病和代谢疾病的治疗剂。 此外，本发明涉及优选形式为冻干物或液体缓冲溶液或人造母乳制剂或含有Val-Tyr-Pro-Asn-Gly-Ala-Glu-Asp-Glu-Ser- Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH任选地与至少一种药学上可接受的载体，冷冻保护剂，冻干保护剂，赋形剂和/或稀释剂一起。
-
公开(公告)号：WO2009040051A2
公开(公告)日：2009-04-02
申请号：PCT/EP2008/007811
申请日：2008-09-09
Applicant: MONDOBIOTECH LABORATORIES AG , BEVEC, Dorian , CAVALLI, Fabio , CAVALLI, Vera , BACHER, Gerald
Inventor： BEVEC, Dorian , CAVALLI, Fabio , CAVALLI, Vera , BACHER, Gerald
IPC: A61K38/44 , A61K38/08 , A61P3/00 , A61P9/00 , A61P11/00 , A61P25/28 , A61P31/00 , A61P35/00 , A61P37/00
CPC classification number: A61K38/085 , A61K38/35 , Y02A50/385 , Y02A50/402 , Y02A50/409 , Y02A50/411 , Y02A50/414 , Y02A50/415 , Y02A50/422 , Y02A50/423
Abstract: The present invention is directed to the use of the peptide compound Ac-Arg-Phe-Met-Trp-Met-Lys-NH 2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquide buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Ac-Arg-Phe-Met-Trp-Met-Lys-NH 2 optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.
Abstract translation: 本发明涉及肽化合物Ac-Arg-Phe-Met-Trp-Met-Lys-NH2作为治疗剂用于预防和/或治疗癌症，自身免疫性疾病，纤维化疾病，炎性疾病， 神经变性疾病，传染病，肺部疾病，心脏和血管疾病以及代谢疾病。 此外，本发明涉及优选形式为冻干物或液体缓冲溶液或人造母乳制剂或含有Ac-Arg-Phe-Met-Trp-Met-Lys-NH 2肽的母乳代用品的药物组合物， 一种药学上可接受的载体，低温保护剂，冻干保护剂，赋形剂和/或稀释剂。
-
9.发明申请METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF DIABETIC AND AGED SKIN 审中-公开用于预防和治疗糖尿病和老化皮肤的方法和组合物
公开(公告)号：WO2007026356A3
公开(公告)日：2008-11-13
申请号：PCT/IL2006001001
申请日：2006-08-29
Applicant: HEALOR LTD , TENNENBAUM TAMAR , BRAIMAN-WIKSMAN LIORA , SOLOMONIK INESSA , MEIR MICHAL
Inventor： TENNENBAUM TAMAR , BRAIMAN-WIKSMAN LIORA , SOLOMONIK INESSA , MEIR MICHAL
CPC classification number: A61K38/28 , A61K31/427 , A61K31/445 , A61K38/02 , A61K38/085 , A61K38/1709 , A61K38/191 , A61K38/2006 , A61K38/2026 , A61K38/204 , A61K38/2053 , A61K38/2264 , A61K38/2271 , A61K38/45 , A61K38/4886 , A61K38/57
Abstract: Method and compositions are provided for treating or preventing a skin pathology or disorder associated with diabetes and/or aging, by topical administration of at least one agent capable of restoring an impaired physiological condition of the skin associated with said skin pathology or disorder. Examples of such agents include PKC modulating agents, various adipokines and insulin signaling related molecules. In particular, restoration of the subcutaneous adipose tissue can overcome many of the diabetic skin pathologies and aging skin disorders and conditions.
Abstract translation: 提供了通过局部施用至少一种能够恢复与所述皮肤病理学或病症相关的皮肤的生理条件受损的药剂来治疗或预防与糖尿病和/或衰老相关的皮肤病理学或病症的方法和组合物。 这些试剂的实例包括PKC调节剂，各种脂肪因子和胰岛素信号传导相关分子。 特别地，皮下脂肪组织的恢复可以克服许多糖尿病皮肤病理学和老化的皮肤病症和病症。
-
10.发明申请INHIBITION OF EXTRACELLULAR SIGNAL-REGULATED KINASE 1/2 AS A TREATMENT FOR CARDIAC HYPERTROPHY AND HEART FAILURE 审中-公开抑制细胞外信号调节激酶1/2作为治疗心肌肥厚和心力衰竭的药物
公开(公告)号：WO2007014033A3
公开(公告)日：2007-07-12
申请号：PCT/US2006028363
申请日：2006-07-21
Applicant: UNIV COLORADO REGENTS , SUCHAROV CARMEN C , BRISTOW MICHAEL C
Inventor： SUCHAROV CARMEN C , BRISTOW MICHAEL C
CPC classification number: G01N33/5061 , A61K38/085 , A61K38/1709 , A61K38/2242 , A61K38/2285 , A61K45/06 , A61K48/00 , C12N15/113 , C12N15/86 , C12N2310/14 , C12N2710/10343 , G01N33/6875 , G01N2333/4703 , G01N2333/715 , G01N2500/02 , G01N2500/10 , G01N2800/325 , A61K2300/00
Abstract: The present invention provides for methods of treating and preventing cardiac hypertrophy and heart failure. The present invention provides the link between ERK1/2 and calcineurin and CamKII. The present invention further demonstrates that inhibitors of ERKl /2 inhibit cardiac hypertrophy and heart disease by inhibiting, in part, the fetal cardiac gene expression that occurs when Ca2+-dependent signalling occurs in the heart.
Abstract translation: 本发明提供了治疗和预防心脏肥大和心力衰竭的方法。 本发明提供了ERK1 / 2与钙调磷酸酶和CamKII之间的联系。 本发明进一步证明ERK1 / 2抑制剂通过部分抑制在心脏中发生Ca2 + - 依赖性信号传导时发生的胎儿心脏基因表达，抑制心脏肥大和心脏疾病。
-
-
-
-
-
-
-
-
-
Search Results
179
records
(took 0.025 seconds)
